TGTX Q4 2020 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38,000+0.0% YoY

Gross Profit

-$68,000-178.9% margin

Operating Income

-$87M-228373.7% margin

Net Income

-$88M-232152.6% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$52M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$626M

Total Liabilities

$106M

Stockholders' Equity

$519M

Cash & Equivalents

$553M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38,000	$38,000	+0.0%
Gross Profit	-$68,000	-$169M	+100.0%
Operating Income	-$87M	-$38M	-128.6%
Net Income	-$88M	-$40M	-122.9%